@article{2a8c01177e004d83b7fc7be4e145c39d,
title = "Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial",
keywords = "Non-small cell lung cancer, NSCLC, Chemotherapy, Radiotherapy, Cancer immunotherapy, Immune checkpoint inhibitors, PD-1 inhibitor, Nivolumab, Combination treatment",
author = "S. Peters and E. Felip and U. Dafni and C. Belka and M. Guckenberger and A. Irigoyen and E. Nadal and A. Becker and H. Vees and M. Pless and A. Martinez-Marti and A. Tufman and M. Lambrecht and N. Andratschke and Piguet, {A. C.} and M. Kassapian and H. Roschitzki-Voser and M. Rabaglio-Poretti and Stahel, {R. A.} and J. Vansteenkiste and {De Ruysscher}, D.",
year = "2019",
month = jul,
doi = "10.1016/j.lungcan.2019.05.001",
language = "English",
volume = "133",
pages = "83--87",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
}